NEW YORK, May 4—Danish pharmaceutical company Novo Nordisk has selected the healthcare practice at Weber Shandwick Worldwide to handle the $500,000 public relations program for NovoSeven, a new recombinant blood coagulation product for people with hemophilia. The account team will be led by executive vice president Sandra Powers, whose firm—the former Brown Powers & Associates—was acquired by Shandwick four years ago to provide the foundation for its health practice.
In clinical trials, NovoSeven was proven safe and effective for people with hemophilia with inhibitors who fail to respond to existing drug treatments. Weber Shandwick Worldwide will handle media relations to medical trade journals and business press.
Weber Shandwick has handle project work for Novo Nordisk over the past two years, but this is its first major assignment from the company.